Standard BioTools Appoints Alex Kim as Chief Financial Officer
Standard BioTools (Nasdaq: LAB) has appointed Alex Kim as Chief Financial Officer, effective November 11, 2024. Kim, a co-founder and former Chief Operating Officer of Standard BioTools, brings nearly 30 years of healthcare and life sciences industry experience. Previously, he served as President of Milliken's Healthcare Division and held leadership positions at Pall and Danaher Throughout his career, Kim has completed over 40 transactions in healthcare, medical technology, and life sciences sectors. Concurrent with Kim's appointment, Jonathan Mickelsen has been promoted to Vice President & Chief Accounting Officer.
Standard BioTools (Nasdaq: LAB) ha nominato Alex Kim come Chief Financial Officer, con effetto dall'11 novembre 2024. Kim, co-fondatore e ex Chief Operating Officer di Standard BioTools, vanta quasi 30 anni di esperienza nell'industria sanitaria e delle scienze della vita. In precedenza, ha ricoperto il ruolo di Presidente della Divisione Healthcare di Milliken e ha occupato posizioni di leadership presso Pall e Danaher. Nel corso della sua carriera, Kim ha completato oltre 40 transazioni nei settori della sanità, della tecnologia medica e delle scienze della vita. In concomitanza con la nomina di Kim, Jonathan Mickelsen è stato promosso a Vice Presidente e Chief Accounting Officer.
Standard BioTools (Nasdaq: LAB) ha nombrado a Alex Kim como Director Financiero, con efecto a partir del 11 de noviembre de 2024. Kim, cofundador y ex Director de Operaciones de Standard BioTools, aporta casi 30 años de experiencia en la industria de la salud y ciencias de la vida. Anteriormente, ocupó el cargo de Presidente de la División de Salud de Milliken y desempeñó funciones de liderazgo en Pall y Danaher. A lo largo de su carrera, Kim ha completado más de 40 transacciones en los sectores de salud, tecnología médica y ciencias de la vida. Concurrentemente con la designación de Kim, Jonathan Mickelsen ha sido ascendido a Vicepresidente y Director de Contabilidad.
표준 생명과학 (Nasdaq: LAB)은 알렉스 김을 2024년 11월 11일부터 최고 재무 책임자로 임명했습니다. 김은 표준 생명과학의 공동 창립자이자 이전 최고 운영 책임자로, 의료 및 생명 과학 산업에서 거의 30년의 경험을 가지고 있습니다. 이전에는 밀리켄 헬스케어 부문 사장으로 재직했으며, 팔(Pall)과 다나허(Danaher)에서의 리더십 역할을 수행했습니다. 그의 경력 동안 김은 헬스케어, 의료 기술 및 생명 과학 분야에서 40건 이상의 거래를 완료했습니다. 김의 임명과 동시에 조너선 미켈슨은 부사장 겸 최고 회계 책임자로 승진했습니다.
Standard BioTools (Nasdaq: LAB) a nommé Alex Kim au poste de directeur financier, avec effet à partir du 11 novembre 2024. Kim, co-fondateur et ancien directeur des opérations de Standard BioTools, possède près de 30 ans d'expérience dans l'industrie de la santé et des sciences de la vie. Auparavant, il avait été président de la division santé de Milliken et avait occupé des postes de direction chez Pall et Danaher. Au cours de sa carrière, Kim a réalisé plus de 40 transactions dans les secteurs de la santé, de la technologie médicale et des sciences de la vie. Parallèlement à la nomination de Kim, Jonathan Mickelsen a été promu vice-président et directeur comptable.
Standard BioTools (Nasdaq: LAB) hat Alex Kim zum Chief Financial Officer ernannt, mit Wirkung zum 11. November 2024. Kim, Mitbegründer und ehemaliger Chief Operating Officer von Standard BioTools, bringt nahezu 30 Jahre Erfahrung in der Gesundheits- und Lebenswissenschaftsbranche mit. Zuvor war er Präsident der Healthcare-Division von Milliken und hatte Führungspositionen bei Pall und Danaher inne. Im Laufe seiner Karriere hat Kim über 40 Transaktionen im Gesundheits-, Medizintechnik- und Lebenswissenschaftssektor abgeschlossen. Parallel zu Kims Ernennung wurde Jonathan Mickelsen zum Vice President und Chief Accounting Officer befördert.
- Internal promotion maintains continuity with co-founder taking CFO role
- New CFO brings 30 years of relevant industry experience
- Strong M&A background with over 40 completed transactions
- None.
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced the appointment of Alex Kim as Chief Financial Officer, effective November 11, 2024. Kim, a co-founder and most recently Chief Operating Officer of Standard BioTools, brings nearly 30 years of financial and operations experience in the healthcare and life sciences industries to the role and will oversee Standard BioTools’ finance organization.
Michael Egholm, President and Chief Executive Officer of Standard BioTools, said, “I am thrilled to announce Alex as our next CFO. Having co-founded Standard BioTools with me, Alex’s deep understanding of our business make him the clear choice for the role and he will continue to be a key architect in the design and implementation of our strategic and financial plans moving forward.”
Prior to joining Standard BioTools, Kim was President of Milliken’s Healthcare Division, initially joining the company in 2015 as Executive Vice President of Corporate Strategy and Corporate Development. From 2012 to 2015, he was Senior Vice President of Strategy and Business Development at Pall Corporation and prior to that from 2002 to 2012, Kim worked at Danaher Corporation in a variety of roles across general management, M&A and business development. Over his career, Kim has completed over 40 transactions, largely focused on healthcare, medical technology and life sciences. He also brings strong operational execution experience, having been intimately involved in integrations and most recently with full operational leadership of a business.
Kim said, “I am delighted to assume the CFO position and continue working alongside Michael and our talented team as we execute the Standard BioTools vision. We have strong momentum and we are moving forward with steadfast focus on operational excellence to achieve our financial targets and long-term growth objectives.”
In connection with this appointment, Jonathan Mickelsen, Standard BioTools’ Vice President and Corporate Controller, has been appointed as the Company’s Vice President & Chief Accounting Officer.
About Standard BioTools Inc.
Standard BioTools Inc. (Nasdaq:LAB), the parent company of SomaLogic Inc. and previously known as Fluidigm Corporation, has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.
For Research Use Only. Not for use in diagnostic procedures.
Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms.
Patent and License Information: standardbio.com/legal/notices.
Trademarks: standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners. ©2024 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.
Investor Contact:
David Holmes
Gilmartin Group LLC
(332) 330-1031
ir@standardbio.com
FAQ
When will Alex Kim start as CFO of Standard BioTools (LAB)?
What was Alex Kim's previous role at Standard BioTools (LAB)?
How many transactions has Alex Kim completed in his career at Standard BioTools (LAB)?
